Role of Sodium-Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review

    January 2025 in “ touchREVIEWS in Endocrinology ”
    A B Kamrul-Hasan, Sunetra Mondal, Fatema Tuz Zahura Aalpona, Lakshmi Nagendra, Deep Dutta
    TLDR SGLT2 inhibitors may help manage PCOS symptoms effectively.
    Sodium–glucose cotransporter-2 inhibitors (SGLT2i) show promise as a therapy for managing polycystic ovary syndrome (PCOS) by improving metabolic and hormonal parameters. These inhibitors can be used alone or in combination with metformin or glucagon-like peptide-1 receptor agonists (GLP1RA), suggesting a versatile approach to treatment. The review highlights the potential of SGLT2i in addressing the complex symptoms associated with PCOS, offering a new avenue for therapeutic intervention.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results